

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD  
QUAKERBRIDGE PLAZA, BUILDING 7, Rooms 200 ABC**

July 17, 2019

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

**AGENDA**

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of draft meeting summary for April 17, 2019 meeting
- IV. Secretary's report
- V. Old Business
  - A. WellCare's List of "Other Category" Contents in the PA Denials Report
- VI. New Business
  - A. Proposed protocol for Hereditary Angioedema (HAE ) Drug Products
  - B. Proposed protocol for Urea Cycle Disorder Products
  - C. Proposed protocol for Chelating Agents
  - D. Proposed protocol for Zolgensma<sup>®</sup> (onasemnogene abeparvovec-xioi)
- VII. A. Informational Highlights/Reports
  - 1. DXC Technology/NJ HMO 1<sup>st</sup> Quarter 2019 Prior Authorization Report
  - 2. Summary of DURB Action Items
  - 3. (a) DHS, DHSS and MCO Programs Top Drugs Report (by amount paid and by category)
  - (b) Physician-administered/Antiviral drugs by amount paid
  - (c) Report on major changes in top drugs ranking for July 2019 meeting (if any)B. Medication information:
  - (a) Sleeping Pill Deaths Prompt FDA to Add Strict Warnings for Drugs
  - (b) House lawmakers want to cut DEA waivers for buprenorphine prescriptions
  - (c) FDA Updates and Press Announcements on Angiotensin II Receptor Blocker (ARB) Recalls (Valsartan, Losartan, and Irbesartan)
- VIII. Referenced Material
  - A. Proposed protocol for calcitonin gene-related peptide (CGRP) inhibitors
  - B. Proposed protocol for gout products